Tag Archives: LLY

Top 5 Warren Buffett Stocks To Own For 2018

Berkshire Hathaway Chairman and CEO Warren Buffett

Yesterday, Warren Buffett, the chairman and CEO of Berkshire Hathaway Inc. (NYSE: BRK.A; BRK.B), said he thinks the United States will “work fine” under President Donald Trump.

His reason: America’s got the “secret sauce” – the ability to survive.

“America works,” Buffett told CNBC on Thursday (Jan. 19). “I’ve said this before. It’ll work wonderfully under [former Democratic presidential candidate] Hillary Clinton, and I think it’ll work fine under Donald Trump.”

The billionaire also conceded that he doesn’t think the United States works perfectly, “but you just look at where we go, milestone after milestone. Never bet against America.”

Buffett likewise took the CNBC interview yesterday as an opportunity to reiterate his call to invest now for the long haul…

Top 5 Warren Buffett Stocks To Own For 2018: Snap-On Incorporated(SNA)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Snap-on (SNA)

    Snap-on, which is more than 100 years old, provides hand and power tools for individuals and professionals, including auto-shop tools and auto diagnostic equipment.

  • [By WWW.THESTREET.COM]

    Coming up on this episode of Mad Money: Cramer interviews Nick Pinchuk, CEO of Snap-on (SNA) . Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?

  • [By John Divine]

    Snap-on Incorporated (SNA) is my choice for the Best Stocks for 2016 competition. At a market cap of $10 billion, I doubt it will double over the next year, as some of the smaller companies in this competition might be able to.

    That said, Snap-on, which manufactures and markets hand tools and diagnostic equipment, is a rock-solid company with an attractive valuation and impressive growth. It goes for 22 times earnings, pays a consistent and modest dividend, and has been around since 1920.

    As cars get more tech-heavy and complicated, newer tools and better diagnostics will be needed — and that’s SNA’s bread ‘n’ butter. 

Top 5 Warren Buffett Stocks To Own For 2018: Popeyes Louisiana Kitchen, Inc.(PLKI)

Advisors’ Opinion:

  • [By Daniel Miller]

    While chicken and burgers might not sound like a match made in heaven for dinner, it could be tasty for investors inRestaurant Brands International (NYSE:QSR). The parent company of Burger King agreed to purchase Popeyes Louisiana Kitchen Inc. (NASDAQ:PLKI).

  • [By Monica Gerson]

    Popeyes Louisiana Kitchen Inc (NASDAQ: PLKI) is estimated to post its quarterly earnings at $0.64 per share on revenue of $85.31 million.

    SpartanNash Co (NASDAQ: SPTN) is expected to post its quarterly earnings at $0.49 per share on revenue of $2.28 billion.

  • [By Ashley Moore]

    Popeyes Louisiana Kitchen Inc. (Nasdaq: PLKI) stock is up 19% today (Tuesday) after Burger King’s parent company, Restaurant Brands International Inc. (NYSE: QSR), announced it will buy the fast-food chicken company.

Top 5 Warren Buffett Stocks To Own For 2018: Cummins Inc.(CMI)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    There are lots of stories like that out there these days. People were perplexed about the Illinois Tool Works (ITW) and Cummins Engine (CMI) and Caterpillar (CAT) quarters, but they turned out to be classic buying opportunities after years of being sell opportunities if the stocks had run. I can’t explain to you how amazing that is. Here are three stocks that have spent months and months in purgatory when they have missed or guided down or slashed forecasts. Now they are up gigantically.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Salesforce.com (CRM) , Paccar (PCAR) , Cummins (CMI) , ConocoPhillips (COP) , Adobe Systems (ADBE) , Annaly Capital (NLY) and Hewlett Packard Enterprise (HPE) .

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Friday was Cummins Inc. (NYSE: CMI) which traded down about 5% at $159.44. The stocks 52-week range is $134.06 to $181.79. Volume was over 3.5 million versus the daily average of 1.2 million shares.

  • [By Reuben Gregg Brewer]

    Making mining equipment has been a horrible business over the last few years. The industry has been hard-hit by the spending cutbacks at mine sites around the world. For example, BHP Billiton Limited trimmed its capital exploration expenditures by roughly 70% between fiscal 2013 and 2016. No wonder Caterpillar Inc. (NYSE:CAT), Komatsu Ltd. (NASDAQOTH:KMTUY), and Cummins Inc. (NYSE:CMI) have been hurting. Only that looks like it’s starting to change, which means this trio could be at the top of a list of mining equipment companies to buy in 2017.

  • [By Reuben Gregg Brewer]

    Ever walk past a construction site? It’s hard not to be enthralled by all the heavy construction machinery moving things around. With the world’s developing economies still building at a relatively fast pace and developing economies, like the United States, in desperate need of upgrading their aging infrastructure, the companies behind that construction machinery could be just as exciting as a construction site in the years ahead. Which is why Caterpillar Inc. (NYSE:CAT), Cummins Inc. (NYSE:CMI), and Terex Corporation (NYSE:TEX) are three of the top construction machinery stocks to look at right now.

Top 5 Warren Buffett Stocks To Own For 2018: Tele Celular Sul Participacoes S.A.(TSU)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Monday, telecommunications services shares fell 0.45 percent. Meanwhile, top losers in the sector included Shenandoah Telecommunications Company (NASDAQ: SHEN), down 3 percent, and TIM Participacoes SA (ADR) (NYSE: TSU) down 2 percent.

Top 5 Warren Buffett Stocks To Own For 2018: Eli Lilly and Company(LLY)

Advisors’ Opinion:

  • [By Dimitra DeFotis]

    Shares of Eli Lilly (LLY) are down nearly 13% this morning after a late-stage Alzheimer’s drug trial failed to produce expected results.

    Biogen(BIIB), down nearly 6% today, also is working on an Alzheimer’s treatment; Merck (MRK) shareswere down 1% in recent trading.

    Lilly was testing the drug as a treatment for mild dementia due to Alzheimer’s disease.Credit Suisse analysts were hopeful the drug trial would show “a statistically significant impact on cognition.”MarketWatch reports:

    “Eli Lilly said it would not pursue approval for the drug to treat mild dementia due to Alzheimers disease and that it will ‘evaluate the impact of these results on the development plans for solanezumab and our other Alzheimers pipeline assets’ … More specifics about the solanezumab drug, expected the night of Dec. 9 during a meeting of the Clinical Trials on Alzheimers Disease (CTAD), could have repercussions for whats called the beta amyloid hypothesis in Alzheimers disease treatments, which target protein fragments that some believe are responsible for the disease …”

    On Nov. 15, J.P. Morgan analysts Chris Schott, Aditi Singhania, Dana Flanders and Christopher Neyor noted that trial success had a low probability. But they kept their$95 price target on the stock, noting the drug pipeline offers other opportunities. Their target implies upside of more than 40% from a recent price near $66. They wrote:

    “… On solanezumab … While the FDA recommends both cognitive and function endpoints for Alzheimers drug approvals, we expect the agency to review solanezumab on the totality of evidence, and we would not be surprised to see a cognitive benefit coupled with a trend in secondary functional endpoints be sufficient for approval … regardless of the solanezumab outcome, we see a diverse range of new product opportunities supporting LLY

  • [By Johanna Bennett]

    Eli Lilly & Co. (LLY) and Biogen (BIIB) are far from the only two drug makers racing to deliver a new treatment for Alzheimers disease. But they are pretty much leading the pack.

    The market for an effective therapy that actually slows the progression of the disease would likely generate billions of dollars in annual sales. It is quite literally the drug industrys version of the holy grail.

    And according to Barclays analysts Geoff Meacham and Paul Choi, the next few weeks could prove to be one of the most fertile periods in Alzheimers disease research since 2008.

    We think the most likely outcome for Lilly’s Phase 3 EXPEDITION 3 (E3) solanezumab trial is the primary cognition (ADAS-Cog14) endpoint is met (just achieving statistical significance with a p-value <0.05) and mixed results on the secondary endpoints including function (ADL), which we believe should be good enough to support a regulatory submission. While aducanumab has a marginally different mechanism of action, we nevertheless expect BIIB shares to trade in sympathy to Lilly.

    Implications for Biogen and Merck: The E3 results are likely to result in volatility for Biogen (up 20-30%, down 10-15%) as Alzheimer’s drives both long-term growth and M&A value even though aducanumab works differently from solanezumab.

    Aducanumab dose titration data is expected at the CTAD meeting (San Diego, Dec. 9). Merck’s Phase 2/3 EPOCH verubecestat (BACE) trial is scheduled to finish in June 2017 but unlike E3, PET scans/CSF tests for A were not an inclusion criteria. We think Merck shares could move 3% to 5% in either direction in sympathy to E3.

    At $76.58, Lillys share price has fallen more than 9% over the past year, while Biogen has climbed more than 9% over the same span.

  • [By Maxx Chatsko]

    Both Evenity and Tymlos are anabolic treatments, which means they encourage bone growth, rather than merely preventing bones from becoming more brittle, as prior generation osteoporosis drugs have done. While Eli Lilly (NYSE:LLY) was the first to market a drug in this class when Forteo gained marketing approval in 2002, it has faced no competitors despite achieving $1.5 billion in global sales last year, including $770 million in the United States. All of its patents expire by August 2019.

  • [By Keith Speights]

    With this rapidly growing market, there are plenty of opportunities for investors. Zoetis (NYSE:ZTS), Merck (NYSE:MRK), and Eli Lilly (NYSE:LLY) stand out as the top animal-health companies to buy in 2017. Here’s why.

  • [By David Zeiler]

    Pharma stocks shot up in the wake of Donald Trump’s victory. Eli Lilly and Co. (NYSE: LLY) and Merck & Co. (NYSE: MRK) both rose about 6%, while Pfizer Inc. (NYSE: PFE) jumped 7%.

Top 5 Safest Stocks To Buy Right Now

Chipotle (NYSE:CMG) is now one of the major focuses of activist investor Bill Ackman after Pershing Square dumped its Valeant Pharmaceuticals (NYSE:VRX) stake. Ackman showed he has the patience to wait out a turnaround, as exhibited with VRX.

However, Ackman is cleaning up his portfolio. He’s also positioned himself, per an SEC filing in March, to be able to sell his near 3 million stake from time to time without having to file multiple registration statements.

Yet, CMG has started to regain strength. The stock is up 25% in 2017. This could give Ackman the encouragement to ride this out. Pershing’s average cost is right around $415 a share.

Top 5 Safest Stocks To Buy Right Now: Netease.com Inc.(NTES)

Advisors’ Opinion:

  • [By Sreekanth Anasa]

    Shares of Hangzhou, China-based NetEase Inc (NASDAQ:NTES)popped 14% in the Feb 16th trading session after the company reported stellar Q4 and full-year 2016 earnings on Feb 15th after market close. The Chinese online gaming giant delivered an EPS of $4.30 on revenues of $1.74B beating EPS estimates by $0.86 and revenue estimates by $16oM. NetEase’s revenue grew by an impressive 53.1% YoY for Q4 and 67.7% for the full year 2016. On the back of these strong numbers, NTES stock closed at an all-time high of $298.73 in yesterday’s trading session. NTES stock might have gone up very high too soon. There could be a correction around the corner but still NTES stock is a great long-term proposition with much more upside left. Here’s why.

  • [By Joe Tenebruso]

    Shares ofNetEase (NASDAQ:NTES)popped 20.1% last month, according to data provided byS&P Global Market Intelligence, as the Chinese internet technology company’s strong fourth-quarter earnings report was applauded by investors.

Top 5 Safest Stocks To Buy Right Now: Eli Lilly and Company(LLY)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Bond prices were much lower early in the day, with yields up by nearly 10 basis points. But fixed income has rallied back (reducing the drop by half on the day). Valeant Pharmaceuticals (VRX) , more weakness. Large pharma lower, led by Eli Lilly (LLY) . Old tech lags, with International Business Machines (IBM) , Intel (INTC) , Cisco Systems (CSCO) and Microsoft (MSFT) all lower. Media roughed up a bit (CBS (CBS) and Comcast (CMCSA) ). The Ugly
    Gold down another $23 to $1,188 (SPDR Gold Trust ETF (GLD) down $2.25). Urban Outfitters (URBN) down $5. NOTE: There will be no “Takeaways” today!   Happy Thanksgiving. Position: Long GLD small, SDS large, JCP large; short SPY, CSCO, CAT small, IWM, TLT small.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’d use today’s weakness to buy Merck (MRK) , Eli Lilly (LLY) , Pfizer (PFE) and Allergan (AGN) , an Action Alerts PLUS holding.

  • [By Chris Lange]

    Eli Lilly & Co. (NYSE: LLY) saw its shares in free fall on Wednesday, not from the usual rhetoric of politicians or even the election, for that matter, but a late-stage trial failure. As 24/7 Wall St. has said time and again, clinical trials can make or break biotech and pharma companies. In this case Eli Lilly hit new 52-week lows, not seen since 2014 and this will not be a loss that Eli Lilly will easily forget. Effectively, the company announced results from its Phase 3 solanezumab trial in people with mild dementia due to Alzheimers disease (AD).

  • [By Johanna Bennett]

    Eli Lilly & Co. (LLY) and Biogen (BIIB) are far from the only two drug makers racing to deliver a new treatment for Alzheimers disease. But they are pretty much leading the pack.

    The market for an effective therapy that actually slows the progression of the disease would likely generate billions of dollars in annual sales. It is quite literally the drug industrys version of the holy grail.

    And according to Barclays analysts Geoff Meacham and Paul Choi, the next few weeks could prove to be one of the most fertile periods in Alzheimers disease research since 2008.

    We think the most likely outcome for Lilly’s Phase 3 EXPEDITION 3 (E3) solanezumab trial is the primary cognition (ADAS-Cog14) endpoint is met (just achieving statistical significance with a p-value <0.05) and mixed results on the secondary endpoints including function (ADL), which we believe should be good enough to support a regulatory submission. While aducanumab has a marginally different mechanism of action, we nevertheless expect BIIB shares to trade in sympathy to Lilly.

    Implications for Biogen and Merck: The E3 results are likely to result in volatility for Biogen (up 20-30%, down 10-15%) as Alzheimer’s drives both long-term growth and M&A value even though aducanumab works differently from solanezumab.

    Aducanumab dose titration data is expected at the CTAD meeting (San Diego, Dec. 9). Merck’s Phase 2/3 EPOCH verubecestat (BACE) trial is scheduled to finish in June 2017 but unlike E3, PET scans/CSF tests for A were not an inclusion criteria. We think Merck shares could move 3% to 5% in either direction in sympathy to E3.

    At $76.58, Lillys share price has fallen more than 9% over the past year, while Biogen has climbed more than 9% over the same span.

  • [By David Zeiler]

    Pharma stocks shot up in the wake of Donald Trump’s victory. Eli Lilly and Co. (NYSE: LLY) and Merck & Co. (NYSE: MRK) both rose about 6%, while Pfizer Inc. (NYSE: PFE) jumped 7%.

Top 5 Safest Stocks To Buy Right Now: SCIENCE APPLICATIONS INTERNATIONAL CORPORATION(SAIC)

Advisors’ Opinion:

  • [By Monica Gerson]

    Wall Street expects Science Applications International Corp (NYSE: SAIC) to report its quarterly earnings at $0.74 per share on revenue of $1.15 billion. SAIC shares gained 0.96 percent to $57.87 in after-hours trading.

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

  • [By Monica Gerson]

    Science Applications International Corp (NYSE: SAIC) is estimated to report its quarterly earnings at $0.74 per share on revenue of $1.15 billion.

Top 5 Safest Stocks To Buy Right Now: ChannelAdvisor Corporation(ECOM )

Advisors’ Opinion:

  • [By Lisa Levin]

    ChannelAdvisor Corp (NASDAQ: ECOM) shares dropped 24 percent to $10.85 following Q4 results. ChannelAdvisor reported Q4 net income of $5.8 million on revenue of $31.8 million.

Top 5 Safest Stocks To Buy Right Now: Medtronic plc(MDT)

Advisors’ Opinion:

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Keith Fitz-Gerald]

    I’ve long thought that Medtronic (NYSE:MDT) would be a suitable buyer, as was the subject of unconfirmed rumors last month. However, I could also envision a defense contractor moving in simply because so much of the intellectual property could easily crossover to military applications. Or, even Google X for that matter.

  • [By George Budwell, Keith Speights, and Cory Renauer]

    So, to help investors separate the wheat from the chaff, we asked our Foolish contributors which stocks they thought are worth owning until at least 2030. These three healthcare specialists recommended Medtronic (NYSE:MDT), Johnson & Johnson (NYSE:JNJ), andIntuitive Surgical (NASDAQ:ISRG). Read on to find out why.

  • [By Todd Campbell]

    At Medtronic (NYSE:MDT), one of the country’s largest medical-device companies, these sensors are even attached to an insulin pump patients wear that canautomatically administer insulin as it’s needed.

  • [By ]

    Medical device makers will also be in the price-control crosshairs. If the government can mandate drug prices, the same can be expected for pacemakers, artificial joints and other devices. Companies such as Medtronic (NYSE: MDT) and previously mentioned pharma giant Johnson & Johnson will find themselves adjusting to a new paradigm.

Top 10 Stocks To Own Right Now

Microsoft stock is trading near its all time high price.

Redmond, Washington-basedtech giant Microsoft (NSDQ:MSFT) may not be one of the exciting names in today’s stock markets. Yet, MSFT stock is up 12.06% YTD, also had an impressive last quarter earningsand the stock is currently trading at an earnings multiple of 29.Satya Nadella wants to turn thePC-centric company into one focussed on the promise of cloud computing. The company has moved its focus from PCs to cloud computing, Enterprise SaaS and innovative hardware (Surface series) to name a few. Can 2017 be Microsoft’s year? Should it be on your buy list heading into 2017? Let’s take a closer look.

How Microsoft has Fared in 2016

The biggest positives for Microsoft Corporation in 2016 would be its triple digit (113% Azure revenue growth) cloud revenue growth and it overtaking salesforce (NYSE:CRM) to become the overall enterprise SaaS market leader. Also, Office 365 increased its customer base to 23.1 M and Dynamics CRM online seat additions, enterprise mobility customers nearly doubled year over year. Surface series revenues growing by 9% ($3.81 B in profit) in the latest quarter can also be counted as apositive. Microsoft’s commercial cloud has also touched an impressive annualized run rate of $12.1 B.

Top 10 Stocks To Own Right Now: SPDR S&P MidCap 400 ETF (MDY)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of REGENTS OF THE UNIVERSITY OF CALIFORNIA’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=REGENTS+OF+THE+UNIVERSITY+OF+CALIFORNIA

    These are the top 5 holdings of REGENTS OF THE UNIVERSITY OF CALIFORNIAiShares J.P. Morgan USD Emerging Markets Bond ETF (EMB) – 229,390 shares, 55.6% of the total portfolio. New PositionThe Estee Lauder Companies Inc (EL) – 33,400 shares, 7.5% of the total portfolio. Exxon Mobil Corp (XOM) – 33,600 shares, 5.74% of the total portfolio. SPDR MidCap Trust Series I (MDY) – 5,600 shares, 3.8% of the total portfolio. New PositionAir Products & Chemicals Inc (APD) – 10,200 shares, 3.21% of the total portfolio. New Purch

  • [By WWW.GURUFOCUS.COM]

    For the details of Cougar Global Investments Ltd’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Cougar+Global+Investments+Ltd

    These are the top 5 holdings of Cougar Global Investments LtdSPDR MidCap Trust Series I (MDY) – 134,036 shares, 37.74% of the total portfolio. Shares added by 9.81%SPDR S&P 500 (SPY) – 150,252 shares, 31.92% of the total portfolio. Shares added by 359.35%iShares Core S&P Small-Cap (IJR) – 374,523 shares, 23.35% of the total portfolio. Shares added by 283.37%iShares MBS (MBB) – 37,334 shares, 3.59% of the total portfolio. Shares added by 109.88%iShares Core U.S. Aggregate Bond (AGG) – 34,781 shares, 3.4% of the

Top 10 Stocks To Own Right Now: Eli Lilly and Company(LLY)

Advisors’ Opinion:

  • [By Dimitra DeFotis]

    Shares of Eli Lilly (LLY) are down nearly 13% this morning after a late-stage Alzheimer’s drug trial failed to produce expected results.

    Biogen(BIIB), down nearly 6% today, also is working on an Alzheimer’s treatment; Merck (MRK) shareswere down 1% in recent trading.

    Lilly was testing the drug as a treatment for mild dementia due to Alzheimer’s disease.Credit Suisse analysts were hopeful the drug trial would show “a statistically significant impact on cognition.”MarketWatch reports:

    “Eli Lilly said it would not pursue approval for the drug to treat mild dementia due to Alzheimers disease and that it will ‘evaluate the impact of these results on the development plans for solanezumab and our other Alzheimers pipeline assets’ … More specifics about the solanezumab drug, expected the night of Dec. 9 during a meeting of the Clinical Trials on Alzheimers Disease (CTAD), could have repercussions for whats called the beta amyloid hypothesis in Alzheimers disease treatments, which target protein fragments that some believe are responsible for the disease …”

    On Nov. 15, J.P. Morgan analysts Chris Schott, Aditi Singhania, Dana Flanders and Christopher Neyor noted that trial success had a low probability. But they kept their$95 price target on the stock, noting the drug pipeline offers other opportunities. Their target implies upside of more than 40% from a recent price near $66. They wrote:

    “… On solanezumab … While the FDA recommends both cognitive and function endpoints for Alzheimers drug approvals, we expect the agency to review solanezumab on the totality of evidence, and we would not be surprised to see a cognitive benefit coupled with a trend in secondary functional endpoints be sufficient for approval … regardless of the solanezumab outcome, we see a diverse range of new product opportunities supporting LLY

  • [By The Ticker Tape]

    Overall, first-quarter earnings have been pretty positive and many CEOs struck an optimistic tone discussing outlooks for the remainder of 2017. Two industrial bellwethers, General Electric Company (NYSE: GE) and Honeywell International Inc. (NYSE: HON), just beat Wall Street analyst expectations on Friday and credit card companies American Express Company (NYSE: AXP) and Visa Inc (NYSE: V) also reported strong results—some are taking that as a sign that consumer confidence could be translating into consumer buying. Next up in Q1, Eli Lilly and Co (NYSE: LLY), Lockheed Martin Corporation (NYSE: LMT), and Caterpillar Inc. (NYSE: CAT) report before market open on April 25.

  • [By WWW.THESTREET.COM]

    Cramer recalled recently investing in Eli Lilly (LLY) on hopes the company’s Alzheimer’s research would be worth billions. As time has worn on, Lilly’s obstacles to success seem to be mounting. Not knowing if or when Lilly might see success, Cramer said he sold the stock and moved on.

  • [By Johanna Bennett]

    Eli Lilly & Co. (LLY) and Biogen (BIIB) are far from the only two drug makers racing to deliver a new treatment for Alzheimers disease. But they are pretty much leading the pack.

    The market for an effective therapy that actually slows the progression of the disease would likely generate billions of dollars in annual sales. It is quite literally the drug industrys version of the holy grail.

    And according to Barclays analysts Geoff Meacham and Paul Choi, the next few weeks could prove to be one of the most fertile periods in Alzheimers disease research since 2008.

    We think the most likely outcome for Lilly’s Phase 3 EXPEDITION 3 (E3) solanezumab trial is the primary cognition (ADAS-Cog14) endpoint is met (just achieving statistical significance with a p-value <0.05) and mixed results on the secondary endpoints including function (ADL), which we believe should be good enough to support a regulatory submission. While aducanumab has a marginally different mechanism of action, we nevertheless expect BIIB shares to trade in sympathy to Lilly.

    Implications for Biogen and Merck: The E3 results are likely to result in volatility for Biogen (up 20-30%, down 10-15%) as Alzheimer’s drives both long-term growth and M&A value even though aducanumab works differently from solanezumab.

    Aducanumab dose titration data is expected at the CTAD meeting (San Diego, Dec. 9). Merck’s Phase 2/3 EPOCH verubecestat (BACE) trial is scheduled to finish in June 2017 but unlike E3, PET scans/CSF tests for A were not an inclusion criteria. We think Merck shares could move 3% to 5% in either direction in sympathy to E3.

    At $76.58, Lillys share price has fallen more than 9% over the past year, while Biogen has climbed more than 9% over the same span.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’d use today’s weakness to buy Merck (MRK) , Eli Lilly (LLY) , Pfizer (PFE) and Allergan (AGN) , an Action Alerts PLUS holding.

Top 10 Stocks To Own Right Now: iShares US Regional Banks (IAT)

Advisors’ Opinion:

  • [By Keith Fitz-Gerald]

    If you’re not comfortable with a single stock, I understand. In that case, consider a regional banking ETF like iShares U.S. Regional Banks ETF (NYSEArca:IAT), which holds positions in 54 regional banks around the country. You won’t get quite the pop of an individual acquisition but, chances are, you won’t lose out either.

Top 10 Stocks To Own Right Now: Big Lots, Inc.(BIG)

Advisors’ Opinion:

  • [By Lisa Levin]

    Big Lots, Inc. (NYSE: BIG) reported upbeat earnings for its third quarter and raised its profit outlook for the year.

    Big Lots posted quarterly earnings of $0.04 per share, on revenue of $1.105 billion. However, analysts were expecting a loss of $0.01 per share on revenue of $1.12 billion.

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, Costco Wholesale(NASDAQ:COST) and Big Lots (NYSE:BIG) were some of the biggest individual movers as investors reacted to details from their latest quarterly earnings reports.

  • [By Peter Graham]

    A long term performance chart shows small cap off-price or value price retailers like Five Belowand Big Lots (NYSE: BIG) along with large capRoss Stores, Inc (NASDAQ: ROST) having at least a positive trend albeit with their share of volatility:

  • [By Peter Graham]

    A long term performance chart shows small cap off-price or value price retailers like Five Belowand Big Lots (NYSE: BIG) along with large capRoss Stores, Inc (NASDAQ: ROST) largely moving into positive territory albeit with their share of volatility:

Top 10 Stocks To Own Right Now: Agrium Inc.(AGU)

Advisors’ Opinion:

  • [By Chad Fraser]

    The agriculture ETF is heavily weighted toward the U.S., with 45.8% of its assets there, but it is geographically diverse, with exposure to countries such as Canada (9.9%), Switzerland (8.5%), Japan (6.7%) and Singapore (5.1%).

    Potash Cartel Breakup Has Weighed on This Agriculture ETF

    The ETF’s unit price declined in the first half of 2013, partly because of the breakup of the Belarusian Potash Company (BPC), through which Russia’s Uralkali, the world’s No. 1 potash producer, and Belaruskali of Belarus distribute their potash. The market is dominated by BPC and Canpotex, owned by Potash Corp. of Saskatchewan (NYSE: POT), Mosaic and Agrium Inc. (NYSE: AGU).

    Together, the two cartels control 70% of global potash exports, so the breakup of BPC will result in a more fractured market, which seems likely to push potash prices lower. Shares of major potash producers fell sharply on the news, as did Market Vectors Agribusiness ETF due to its potash stock holdings, which include Agrium, Potash Corp. and Mosaic.

  • [By Shanthi Rexaline]

    Agri-Input Companies — Seeds/ Fertilizers/Pesticides Manufacturers

    Monsanto Company (NYSE: MON): +68.82 percent since 2011. Syngenta AG (ADR) (NYSE: SYT): +56.26 percent since 2011. Mosaic Co (NYSE: MOS): -63.1 percent since 2011. Potash Corporation of Saskatchewan (USA) (NYSE: POT): -67.8 percent since 2011. CF Industries Holdings, Inc. (NYSE: CF): +5.04 percent since 2011. Agrium Inc. (USA) (NYSE: AGU): +1.10 percent since 2011.

    Agri-Finance Companies

  • [By Jon C. Ogg]

    Gains are being seen elsewhere as well, except in shares of The Mosaic Company (NYSE: MOS). AgriumInc. (NYSE: AGU) was up almost 3% at $91.95 in late Monday trading, although this one held up much better in the destructive news phase when the alarming news roiled these stocks. The big winner is Intrepid Potash, Inc. (NYSE: IPI), with a gain of 7% to $16.20 in late-Monday trading.

Top 10 Stocks To Own Right Now: Madrigal Pharmaceuticals, Inc. (MDGL)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Madrigal (MDGL) has a significant market opportunity to treat NASH. Its MGL-3196 is well positioned as a potential treatment when the illness is at its earliest stages of development, and thereby save the most lives and money.

Top 10 Stocks To Own Right Now: BorgWarner Inc.(BWA)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Yesterday, I dubbed the selloff in auto stocks “car-pocalypse now,” as shares of everything car related tumbled following disappointing auto sales. Shares of General Motors (GM) and Ford Motor (F)? Check. Auto-part makers like BorgWarner (BWA)? Check. Used-car sellers like AutoNation (AN) and CarMax (KMX)? Check. Auto-part retailers like O’Reilly Automotive (ORLY) and AutoZone (AZO)? Oh yeah. So is it time to panic?

  • [By Ben Levisohn]

    Yesterday, Morgan Stanleys Adam Jonas cut Delphi Automotive (DLPH) to Underweight from Overweight citing the threat posed by electric cars (and not just Tesla Motors (TSLA)). Today, Bairds David Leiker and team offer a fuller defense of Delphi Automotive, as well as Borg Warner (BWA) and Lear (LEA):

Top 10 Stocks To Own Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Ben Levisohn]

    Who has PARP? A poly ADP-ribose polymerase inhibitor (PARPi) kills cancer cells by interfering tumor DNA repair pathway with the potential to treat ovarian, breast and prostate cancer. Studies have shown that patients with BRCA mutations (BRCAmut) respond to PARPi. AstraZenecas (AZN) PARPi was approved in 2014 whileClovis Oncology (CLVS) and Tesaro (TSRO) both have positive Phase III data. Clovis licensed its PARPi from Pfizer (PFE) in 2011 and Tesaro licensed its PARPi from Merck (MRK) in 2012, after Sanofis (SNY) PARPi (later demonstrated that it cannot block PARP) failed in Phase III in early 2011.

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

Top 10 Stocks To Own Right Now: Bed Bath & Beyond Inc.(BBBY)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Shares of Bed Bath & Beyond (BBBY) took a bath today, Cramer told viewers, and is likely beyond hope.

    The home-goods retailer posted a huge earnings miss, delivering just 53 cents a share when the analysts were expecting 66 cents a share. Making matters worse, the company also saw a 2% decline in same-store sales.

  • [By Lisa Levin]

    Bed Bath & Beyond Inc. (NASDAQ: BBBY) was down, falling around 12 percent to $29.61 after the company reported weaker-than-expected results for its first quarter.

  • [By Lisa Levin]

    Bed Bath & Beyond Inc. (NASDAQ: BBBY) shares dropped 16 percent to $22.83 as the company reported downbeat earnings for its third quarter.

    Shares of Maxwell Technologies Inc. (NASDAQ: MXWL) were down 15 percent to $5.34. Maxwell reported amended terms for deal with Viex Capital and announced a proposed offering of $50 million convertible senior notes due 2022.

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than

Top 10 Stocks To Own Right Now: United States Steel Corporation(X)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of Steel Dynamics outperforming peers large cap Nucor Corporation (NYSE: NUE) and mid cap United States Steel Corporation (NYSE: X) along with Market Vectors Steel ETF (NYSEARCA: SLX):

  • [By Shanthi Rexaline]

    United States Steel Corporation (NYSE: X) is building on its post-election gains, even as it perches on a two-year high.

    The most recent catalyst being a tweet by CNBC's Brian Sullivan that CEO Mario Longhi revealed plans to rehire up to 10,000 workers previously let gone due to slowing business.

  • [By Peter Graham]

    A long term performance chart shows shares of Steel Dynamics outperforming peers large cap Nucor Corporation (NYSE: NUE) and mid cap United States Steel Corporation (NYSE: X) along with Market Vectors Steel ETF (NYSEARCA: SLX):

Top 10 Low Price Stocks To Buy Right Now

The U.S. Commerce Department backed Boeing in its challenge to Bombardier, recommending an enormous tariff on sales of Bombardier’s C Series jetliner, a major blow to the Canadian plane maker.

The initial ruling by the International Trade Commission, an arm of the Commerce Department, recommends a 219.63% tariff on the delivery of each airliner, according to a person briefed on the ITC’s findings.

Boeing (BA), America’s largest exporter and sole U.S. producer of commercial airliners, is suing Bombardier. At issue is whether Bombardier received financial backing from the Canadian government that allowed the plane maker to stay afloat and sell to Delta for what Boeing alleges were “absurdly low prices.”

“The U.S. values its relationships with Canada, but even our closest allies must play by the rules,” said Commerce Secretary Wilbur Ross in a statement. “The subsidization of goods by foreign governments is something that the Trump Administration takes very seriously, and we will continue to evaluate and verify the accuracy of this preliminary determination.”

Top 10 Low Price Stocks To Buy Right Now: Cimpress N.V(CMPR)

Advisors’ Opinion:

  • [By Steve Symington]

    Shares ofCimpress NV(NASDAQ:CMPR)climbed 14.6% in 2016,according to data from S&P Global Market Intelligence, as the mass customization specialist steadfastly pursued its novel long-term efforts to generate shareholder value.

Top 10 Low Price Stocks To Buy Right Now: Pound/Rand(PX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    The last twelve months haven’t been kind to Praxair (PX) and Air Products & Chemicals (APD), but UBS analyst John Roberts and team argue that’s about to change, as they upgrade their shares to Buy from Neutral arguing that their earnings can withstand a slowing global economy:

    In our view, the two stocks are more alike than different. NTM P/Es are within ~0.5 pts of each other. Both stocks have declined ~20% from their historical highs the largest corrections in 20+ years aside from the financial crisis…

    Industrial gas stocks have normally grown through changes in FX, oil & China demand within normal historical ranges. And investor concerns around China forAir Products & Chemicals may still prove much bigger than reality. Nevertheless, the combination of FX & oil sector impacts on Praxair, and FX & China issues for Air Products & Chemicals, have been much larger than previously seen. With oil already down, the dollar already appreciated, & China concerns already heightened we believe forward basis would appear to carry only normal risks (& lower if FX & oil are mean-reverting, which some theories support).

    Normal high single digit EPS growth projected for both in 2017 vs 2016: Four large firms serve 70%+ of the global merchant gas market, and price normally contributes ~2% to growth. Customer older captive units being outsourced contributes another 2%. Secular drivers for oxygen include energy savings (i.e. O2 burns more efficiently than air), life sciences (healthcare & microbial processes) nitrogen secular drivers include increasing purity requirements (food freezing & semiconductors). Topline growth ~2x global GDP more normal, with EPS growth ~2x sales growth due to high fixed costs (key variable costs are inexpensive air & power).

    Financial crisis demand drop was only a few %, in line with global GDP drop Most chemicals volumes dropped 10%+ (some 40%

Top 10 Low Price Stocks To Buy Right Now: U.S. Bancorp(USB)

Advisors’ Opinion:

  • [By John Maxfield]

    One of this era’s most successful bankers has decided to relinquish the reins. U.S. Bancorp (NYSE:USB) announced on Tuesday that chairman and CEO Richard Davis will step down from his role as CEO at the bank’s annual meeting in April. He’ll stay on as executive chairman of the board, while President and COO Andy Cecere will succeed him in the corner office.

  • [By Sarfaraz Khan]

    In addition to this, Warren Buffett has also built sizable positions in a number of major US banks.Wells Fargo (NYSE:WFC), U.S. Bancorp (NYSE:USB)and Goldman Sachs (NYSE:GS)have the leading positions in Berkshire Hathaways portfolio. In fact, Wells Fargo is Berkshire Hathaway’s second largest stock holding. In addition to this, Berkshire Hathaway also owns $5 billion worth of Bank of Americas preferred shares and warrants to buy 700 million of the banks ordinary shares at just $7.14 (current price $22.10) anytime until September 2021. These banks are positioned to become the biggest beneficiaries of the increase in interest rates. To get an idea of how this might happen, consider Bank of Americas forecast in which it predicted a $7.5 billion boost to annual net interest income following a 1-percentage-point increase in interest rates.

Top 10 Low Price Stocks To Buy Right Now: Washington Trust Bancorp, Inc.(WASH)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

Top 10 Low Price Stocks To Buy Right Now: SPDR Wells Fargo Preferred Stock ETF (PSK)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    DWFI holds five other SSgA fixed income ETFs, including the SPDR Wells Fargo Preferred Stock ETF (NYSE: PSK). PSK is DWFI's largest holding at a weight of 25.2 percent. DWFI's second-largest holding is an allocation of almost 25 percent to the SPDR Nuveen Barclays Municipal Bond ETF (NYSE: TFI).

Top 10 Low Price Stocks To Buy Right Now: (PIONF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    International Lithium (ILC) is a small lithium explorer/project generator with four joint venture lithium projects, and one fully-owned lithium project:

    Mariana lithium brine in Argentina (20% ILC: 80% GFL). ILC can increase to 30% via a 10% back-in right. Jiangxi Ganfeng Lithium (GFL) is committed to US$10m in expenditures at Mariana. This is their flagship project. Avalonia lithium pegmatite in Ireland (45% ILC: 55% GFL). GFL has the option to acquire an additional 24% after spending US$10m, or producing a Feasibility Study [FS]. Mavis Lake and Raleigh lithium pegmatite in Ontario Canada (49% ILC: 51% Pioneer Resources Limited (OTC:PIONF)). 100% of the Forgan Lake pegmatite project in Canada.

    Note that Avalon, Mavis Lake, Raleigh, and Forgan Lake also have rare earths. Jiangxi Ganfeng Lithium (SHE:002460) has an 18.1% stake in ILC in addition to the above joint venture partnerships.

Top 10 Low Price Stocks To Buy Right Now: Columbia Sportswear Company(COLM)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Looking at recent historical deals, we arrive at a $18-$23 potential deal range. We analyzed transactions that have been announced over the past four years and involved companies catering to a higher income customer. These deals include Southern Tide (acquired by Oxford Industries (OXM)), Joe’s Jeans (acquired by Sequential Brands Group (SQBG)), prAna (acquired by Columbia Sportswear (COLM)), The Jones Group (acquired by Sycamore Partners [private] and Juicy Couture (acquired by Authentic Brands Group [private]). The average EV/EBITDA multiple of these transactions are 12.9x (in line with KATE’s 5-year historical average of 12.1x) and implies a potential deal range of $22-$23. When taking the average of recent (F13-16) deals implies an ~10.5x EV/EBITDA multiple. When applying the ~10.5x multiples to KATE’s trailing EBITDA, we arrive at an $18- $19 potential share price.

  • [By D.R. Barton, Jr.]

    I bring Mr. Houdini up today because when I look at our favorite “Pop & Drop” play – Columbia Sportswear Co. (Nasdaq: COLM) – I find an eerie similarity to this great “escapesman.”

  • [By Peter Graham]

    A long term performance chart shows mid cap Under Armourpreviously outperforming peers like large cap Nike Inc (NYSE: NKE) and mid cap Columbia Sportswear Company (NASDAQ: COLM), but that outperformance slipped late last year:

  • [By Matt Hogan]

    SKX is also highly attractive in a relative basis when compared to several of its publicly traded peers: Foot Locker, Inc. (NYSE: FL), Deckers Outdoor Group (NYSE: DECK), Wolverine World Wide, Inc. (NYSE: WWW) and Columbia Sportswear Company (NASDAQ: COLM). The company's forward EBITDA multiple of 6.9x is equal or below all of the comparable companies: FL (6.9x), DECK (7.6x), WWW (10.1x) and COLM (10.8x).

Top 10 Low Price Stocks To Buy Right Now: Ryerson Holding Corporation(RYI)

Advisors’ Opinion:

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, PriceSmart (NASDAQ:PSMT) and Ryerson (NYSE:RYI)attracted heavy investor interest in the wake of their quarterly earnings reports.

  • [By Dan Caplinger]

    Among the worst performers on the day were GameStop (NYSE:GME), Hovnanian Enterprises (NYSE:HOV), and Ryerson Holding (NYSE:RYI). Below, we’ll look more closely at these stocks to explain why they did so poorly.

  • [By Lisa Levin]

    Shares of Ryerson Holding Corp (NYSE: RYI) got a boost, shooting up 11 percent to $13.70. Ryerson expects Q1 net income of $12 million to $15 million.

Top 10 Low Price Stocks To Buy Right Now: Eli Lilly and Company(LLY)

Advisors’ Opinion:

  • [By Chris Lange]

    Eli Lilly & Co. (NYSE: LLY) saw its shares in free fall on Wednesday, not from the usual rhetoric of politicians or even the election, for that matter, but a late-stage trial failure. As 24/7 Wall St. has said time and again, clinical trials can make or break biotech and pharma companies. In this case Eli Lilly hit new 52-week lows, not seen since 2014 and this will not be a loss that Eli Lilly will easily forget. Effectively, the company announced results from its Phase 3 solanezumab trial in people with mild dementia due to Alzheimers disease (AD).

  • [By WWW.THESTREET.COM]

    Bond prices were much lower early in the day, with yields up by nearly 10 basis points. But fixed income has rallied back (reducing the drop by half on the day). Valeant Pharmaceuticals (VRX) , more weakness. Large pharma lower, led by Eli Lilly (LLY) . Old tech lags, with International Business Machines (IBM) , Intel (INTC) , Cisco Systems (CSCO) and Microsoft (MSFT) all lower. Media roughed up a bit (CBS (CBS) and Comcast (CMCSA) ). The Ugly
    Gold down another $23 to $1,188 (SPDR Gold Trust ETF (GLD) down $2.25). Urban Outfitters (URBN) down $5. NOTE: There will be no “Takeaways” today!   Happy Thanksgiving. Position: Long GLD small, SDS large, JCP large; short SPY, CSCO, CAT small, IWM, TLT small.

  • [By WWW.THESTREET.COM]

    Cramer recalled recently investing in Eli Lilly (LLY) on hopes the company’s Alzheimer’s research would be worth billions. As time has worn on, Lilly’s obstacles to success seem to be mounting. Not knowing if or when Lilly might see success, Cramer said he sold the stock and moved on.

  • [By Keith Speights]

    With this rapidly growing market, there are plenty of opportunities for investors. Zoetis (NYSE:ZTS), Merck (NYSE:MRK), and Eli Lilly (NYSE:LLY) stand out as the top animal-health companies to buy in 2017. Here’s why.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’d use today’s weakness to buy Merck (MRK) , Eli Lilly (LLY) , Pfizer (PFE) and Allergan (AGN) , an Action Alerts PLUS holding.

  • [By Johanna Bennett]

    Eli Lilly & Co. (LLY) and Biogen (BIIB) are far from the only two drug makers racing to deliver a new treatment for Alzheimers disease. But they are pretty much leading the pack.

    The market for an effective therapy that actually slows the progression of the disease would likely generate billions of dollars in annual sales. It is quite literally the drug industrys version of the holy grail.

    And according to Barclays analysts Geoff Meacham and Paul Choi, the next few weeks could prove to be one of the most fertile periods in Alzheimers disease research since 2008.

    We think the most likely outcome for Lilly’s Phase 3 EXPEDITION 3 (E3) solanezumab trial is the primary cognition (ADAS-Cog14) endpoint is met (just achieving statistical significance with a p-value <0.05) and mixed results on the secondary endpoints including function (ADL), which we believe should be good enough to support a regulatory submission. While aducanumab has a marginally different mechanism of action, we nevertheless expect BIIB shares to trade in sympathy to Lilly.

    Implications for Biogen and Merck: The E3 results are likely to result in volatility for Biogen (up 20-30%, down 10-15%) as Alzheimer’s drives both long-term growth and M&A value even though aducanumab works differently from solanezumab.

    Aducanumab dose titration data is expected at the CTAD meeting (San Diego, Dec. 9). Merck’s Phase 2/3 EPOCH verubecestat (BACE) trial is scheduled to finish in June 2017 but unlike E3, PET scans/CSF tests for A were not an inclusion criteria. We think Merck shares could move 3% to 5% in either direction in sympathy to E3.

    At $76.58, Lillys share price has fallen more than 9% over the past year, while Biogen has climbed more than 9% over the same span.

Top 10 Low Price Stocks To Buy Right Now: Cabot Oil & Gas Corporation(COG)

Advisors’ Opinion:

  • [By David Sterman]

    Take Cabot Oil & Gas (NYSE: COG(link is external)) as an example. As I noted earlier this month(link is external), Cabot’s current drilling plans are expected to lead to a big spike in output over the next few years. The company’s executives decided to plow ahead with development plans, even as rivals were retrenching. The fact that natural gas prices have risen more than 10% in the past three weeks simply underscores the wisdom of that strategy, and could lead to rising sales and profit estimates. 

  • [By Paul Ausick]

    Cabot Oil & Gas Corp. (NYSE: COG) is rated as a Hold with a new price target of $24. The EPS estimate has been cut from $0.60 to $0.47 for 2017, and the 2018 estimate has been increased from $0.70 to $1.19. Shares closed at $22.36 on Friday in a 52-week range of $19.77 to $25.74. The consensus 12-month price target is $28.72.